Research increasingly suggests physicians can convey bias under “the guise of objective descriptions” found in medical records, Kaiser Health News reported Sept. 26.
Category: ROOT
13 most popular medical, non-medical side gigs for physicians
Thirty-seven percent of physicians reported having a side gig in 2022 according to the Physician Extra Income report from Medscape.
How much young physicians made in 2022
Young physicians overall made $293,000 in 2022, according to Medscape’s “Young Physician Compensation Report 2022.”
4 steps to protecting wealth in a recession
With 52 percent of economists warning of an impending recession in the next 12 months, there are four steps Americans can take to protect their personal wealth, according to a Sept. 23 report from CNBC.
How Americans feel about a possible recession: 9 facts
More than half of Americans (56 percent) believe that the U.S. economy is already in a recession, according to a new survey of 1,500 adults commissioned by life insurance company MassMutual.
What Optum gets in the Change Healthcare deal
UnitedHealth Group is moving forward with plans to merge healthcare data and analytics giant Change Healthcare with Optum after a judge cleared the path for the multibillion-dollar transaction Sept. 19.
Whitsett Vision Group debuts lens for cataract surgeries
Houston-based Whitsett Vision Group has become the first ophthalmology group in the country to perform a cataract surgery using a new FDA-approved lens, the Lenstec ClearView 3.
Illinois hospital ending inpatient pediatric services
FHN Memorial Hospital in Freeport, Ill., is discontinuing inpatient pediatric services, effective Oct. 3.
A new ‘striketober’?
Last year, a movement of labor actions was deemed “striketober” online and on social media as union workers in healthcare and other industries walked off the job or threatened to do so. Now the possibility of another “striketober” looms amid increased …
HHS to pay for 60K doses of Eli Lilly’s COVID-19 drug following its commercialization
The federal government said Sept. 23 that it will cover the cost for 60,000 doses of bebtelovimab, Eli Lilly’s COVID-19 antibody drug. The news comes about a month after the drugmaker started selling the treatment commercially for $2,000 per dose.
